Evidence map›Paper›PMID 39896505›Full record

ArticlebioRxiv : the preprint server for biology2025

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Erica M Pimenta, Amanda E Garza, Sabrina Y Camp, Jihye Park, Samantha E Hoffman, Laura Valderrábano, Jingxin Fu, Kevin Bi, Julie Karam, Breanna M Titchen and 12 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Erica M PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Amanda E GarzaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Samantha E HoffmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Laura ValderrábanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jingxin FuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Julie KaramDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Breanna M TitchenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Melin J KhandekarDavid Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Yun Jee KangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Anwesha NagDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Aaron R ThornerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Chandrajit P RautSarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jason L HornickSarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Priscilla MerriamDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Nicole L SoliminiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Suzanne GeorgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
George D DemetriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-0201-4444

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney CancerR01CA278980 · NCI · DANA-FARBER CANCER INST · PI Eliezer M Van Allen · 2024 to 2026
$2.1M
Molecular origins and evolution to treatment resistance in genitourinary cancersR50CA265182 · NCI · DANA-FARBER CANCER INST · PI Jihye Park · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA278980NCI NIH HHS R37 CA222574NCI NIH HHS R50 CA265182NCI NIH HHS T32 CA009172NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Sarcomas are rare connective tissue cancers thought to arise from aberrant mesenchymal stem cell (MSC) differentiation. Liposarcoma (LPS) holds valuable insights into dysfunctional differentiation given its well- and dedifferentiated histologic subtypes (WDLPS, DDLPS). Despite well-established differences in histology and clinical behavior, the molecular pathways underlying each subtype are poorly understood. Here, we performed single-nucleus multiome sequencing and spatial profiling on carefully curated human LPS samples and found defects in adipocyte-specific differentiation within LPS. Loss of insulin-like growth factor 1 (IGF1) and gain of cellular programs related to early mesenchymal development and glucagon-like peptide-1 (GLP-1)-induced insulin secretion are primary features of DDLPS. IGF1 loss was associated with worse overall survival in LPS patients. Through

Identifiers

PMID39896505
PMCPMC11785083

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.